JO DRENNAN: Open Payments
NPI 1326659772 · BILOXI, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,230 in 136 payments from 14 companies in 2025. Trend: 2023 $143 · 2024 $247 · 2025 $3,230
Food & beverage: $3,181Education: $49
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 27 | $719 |
| Janssen Pharmaceuticals, Inc | 30 | $470 |
| ABBVIE INC. | 19 | $412 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $294 |
| Vanda Pharmaceuticals Inc. | 10 | $250 |
| Teva Pharmaceuticals USA, Inc. | 9 | $246 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $201 |
| Lundbeck LLC | 7 | $146 |
| Boston Scientific Corporation | 1 | $125 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $120 |
Products named: Auvelity, VRAYLAR, SPRAVATO, CAPLYTA, FANAPT, TRINTELLIX, AUSTEDO XR, Intracept.
Industry payments across MS — which companies pay providers there.
